Allergios develops an in-vitro allergy diagnostic system that directly visualizes the allergic response using patient blood serum. This method analyzes allergen-specific degranulation of basophil cells via a disposable microfluidic chip and optical reader. The platform aims to provide safe, unambiguous allergy diagnoses, initially focusing on replacing cumbersome food challenge testing.
Funding
$700K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current allergy tests, such as skin prick tests and IgE blood tests, often indicate sensitization to allergens but do not always confirm an actual allergic reaction. The double-blind placebo-controlled food challenge, the current gold standard, can induce severe reactions and is burdensome, time-consuming, and costly.
Solution
Allergios offers a direct in-vitro allergy diagnostic test that visualizes basophil degranulation in response to specific allergens. The test utilizes a microfluidic chip and optical reader (GranulEye®) to analyze how blood serum enables allergen-specific degranulation of basophil cells. This method provides a clear and accurate diagnosis of allergies, enabling clinicians to provide timely and effective treatment options based on unambiguous results. The company initially focuses on food allergies, aiming to replace the food challenge test and skin prick test, and plans to expand to inhalant and other IgE-mediated allergies.
Target Audience
The primary target audience includes clinicians, allergists, and hospitals seeking a more reliable and accurate method for diagnosing food and other IgE-mediated allergies.
Features
- Disposable microfluidic chip for safe and easy allergy testing
- GranulEye® optical reader for visualizing basophil degranulation
- AI-based analysis software for interpreting test results
- Direct measurement of basophil degranulation, indicating an actual allergic response
- In-vitro diagnostic, eliminating the risk of severe allergic reactions during testing